SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001104659-21-023425
Filing Date
2021-02-16
Accepted
2021-02-16 12:06:38
Documents
1
Group Members
DAN OREN

Document Format Files

Seq Description Document Type Size
1 SC 13G/A tm216121d2_sc13ga.htm SC 13G/A 48271
  Complete submission text file 0001104659-21-023425.txt   50002
Mailing Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 2161401
Business Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 2161401 972-4-988-9488
Protalix BioTherapeutics, Inc. (Subject) CIK: 0001006281 (see all company filings)

IRS No.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-50118 | Film No.: 21634750
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 1 DEXCEL STREET OR AKIVA L3 3060000
Business Address 1 DEXCEL STREET OR AKIVA L3 3060000 97246364040
Dexcel Pharma Technologies Ltd. (Filed by) CIK: 0001720007 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: SC 13G/A